Logo image of UTRS

MINERVA SURGICAL INC (UTRS) Stock Price, Forecast & Analysis

USA - NASDAQ:UTRS - US60343F2056 - Common Stock

1.48 USD
-0.07 (-4.52%)
Last: 12/28/2023, 8:06:43 PM
1.53 USD
+0.05 (+3.38%)
After Hours: 12/28/2023, 8:06:43 PM

UTRS Key Statistics, Chart & Performance

Key Statistics
Market Cap13.14M
Revenue(TTM)51.69M
Net Income(TTM)-33.45M
Shares8.88M
Float2.73M
52 Week High14
52 Week Low1.37
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-8.21
PEN/A
Fwd PEN/A
Earnings (Next)03-19 2024-03-19/amc
IPO2021-10-22
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


UTRS short term performance overview.The bars show the price performance of UTRS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

UTRS long term performance overview.The bars show the price performance of UTRS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of UTRS is 1.48 USD. In the past month the price decreased by -5.13%. In the past year, price decreased by -66.88%.

MINERVA SURGICAL INC / UTRS Daily stock chart

UTRS Latest News, Press Relases and Analysis

UTRS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 26.17 227.29B
ISRG INTUITIVE SURGICAL INC 63.82 196.99B
BSX BOSTON SCIENTIFIC CORP 34.81 152.16B
SYK STRYKER CORP 27.5 138.48B
IDXX IDEXX LABORATORIES INC 54.71 55.19B
BDX BECTON DICKINSON AND CO 13.39 55.33B
EW EDWARDS LIFESCIENCES CORP 33.58 50.67B
RMD RESMED INC 24.69 35.68B
GEHC GE HEALTHCARE TECHNOLOGY 15.94 33.40B
DXCM DEXCOM INC 31.22 22.77B
PODD INSULET CORP 72.8 23.42B
ZBH ZIMMER BIOMET HOLDINGS INC 11.11 17.81B

About UTRS

Company Profile

UTRS logo image Minerva Surgical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Redwood City, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. The company offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.

Company Info

MINERVA SURGICAL INC

101 Saginaw Drive

Redwood City CALIFORNIA US

Employees: 174

UTRS Company Website

Phone: 16502843500

MINERVA SURGICAL INC / UTRS FAQ

Can you describe the business of MINERVA SURGICAL INC?

Minerva Surgical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Redwood City, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. The company offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.


What is the stock price of MINERVA SURGICAL INC today?

The current stock price of UTRS is 1.48 USD. The price decreased by -4.52% in the last trading session.


Does UTRS stock pay dividends?

UTRS does not pay a dividend.


What is the ChartMill technical and fundamental rating of UTRS stock?

UTRS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


When does MINERVA SURGICAL INC (UTRS) report earnings?

MINERVA SURGICAL INC (UTRS) will report earnings on 2024-03-19, after the market close.


Who owns MINERVA SURGICAL INC?

You can find the ownership structure of MINERVA SURGICAL INC (UTRS) on the Ownership tab.


What is the outstanding short interest for MINERVA SURGICAL INC?

The outstanding short interest for MINERVA SURGICAL INC (UTRS) is 0% of its float.


UTRS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

UTRS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to UTRS. Both the profitability and financial health of UTRS have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UTRS Financial Highlights

Over the last trailing twelve months UTRS reported a non-GAAP Earnings per Share(EPS) of -8.21. The EPS increased by 58.66% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -45.95%
ROE -164.78%
Debt/Equity 1.37
Chartmill High Growth Momentum
EPS Q2Q%89.88%
Sales Q2Q%-4.92%
EPS 1Y (TTM)58.66%
Revenue 1Y (TTM)3.07%

UTRS Forecast & Estimates

7 analysts have analysed UTRS and the average price target is 3.06 USD. This implies a price increase of 106.76% is expected in the next year compared to the current price of 1.48.

For the next year, analysts expect an EPS growth of 82.41% and a revenue growth 2.99% for UTRS


Analysts
Analysts82.86
Price Target3.06 (106.76%)
EPS Next Y82.41%
Revenue Next Year2.99%

UTRS Ownership

Ownership
Inst Owners0.31%
Ins Owners1799.28%
Short Float %0%
Short Ratio0